Potential inhibitors of angiogenesis. Part II: 3-(azolylmethylene)-2,3-dihydrobenzo[b]furan-2-ones

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 18, Issue 3, 2003, Pages 253-257

  Braud, Emmanuelle ^a   Duflos, Muriel ^a   Le Baut, Guillaume ^a   Renard, Pierre ^b   Pfeiffer, Bruno ^b   Tucker, Gordon ^c  

^a UNIVERSITÉ DE NANTES   (France)

^b INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^c INSTITUT DE RECHERCHES SERVIER   (France)

Author keywords

2,3 dihydrobenzo b furan 2 one; 3 (3,5 dimethylpyrrol 2 ylmethylene) 2,3 dihydrobenzo b furan 2 one; 3 (imidazol 4(5) ylmethylene) 2,3 dihydrobenzo b furan 2 one; 3 (imidazol 4(5) ylmethylene)indolin 2 one; Angiogenesis; Vascular density index (VDI)

Indexed keywords

2 FORMYL 3,5 DIMETHYLPYRROLE; 2 HYDROXYPHENYLACETIC ACID; 2,3 DIHYDROBENZO[B]FURAN 2 ONE DERIVATIVE; 2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 3 (3,5 DIMETHYLPYRROL 2 YLMETHYLENE) 2,3 DIHYDROBENZO[B]FURAN 2 ONE; 3 (AZOLYLMETHYLENE) 2,3 DIHYDROBENZO[B]FURAN 2 ONE DERIVATIVE; 3 (IMIDAZOL 4(5) YLMETHYLENE) 2,3 DIHYDROBENZO[B]FURAN 2 ONE DERIVATIVE; 3 (IMIDAZOL 4(5) YLMETHYLENE)INDOLIN 2 ONE; 3 [(3,5 DIMETHYL 1H PYRROL 2 YL)METHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE DERIVATIVE; 4 FORMYLIMIDAZOLE; ACETIC ACID DERIVATIVE; ACID; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; FURAN DERIVATIVE; IMIDAZOLE DERIVATIVE; PYRROLE DERIVATIVE; SEMAXANIB; UNCLASSIFIED DRUG; VATALANIB;

ANGIOGENESIS; ANIMAL TISSUE; AORTA; ARTICLE; CATALYSIS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DEHYDRATION; DRUG ACTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; IN VITRO STUDY; KNOEVENAGEL CONDENSATION; NONHUMAN; PRIORITY JOURNAL; RAT;

ANGIOGENESIS INHIBITORS; ANIMALS; AORTA; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; INDOLES; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MODELS, CHEMICAL; PYRROLES; RATS; RATS, INBRED F344; TEMPERATURE;

ANIMALIA;

EID: 0037675812     PISSN: 14756366     EISSN: None     Source Type: Journal    
DOI: 10.1080/1475636031000106584     Document Type: Article

References (21)

1. Nicosia, R.F. (1998) Am. J. Pathol. 153, 11-16.
2. Unger, C. (1997) Drugs Future 22, 1337-1345.
3. Sorbera, L.A., Castaner, R.M. and Leeson, P.A. (2000) Drugs Future 25, 551-557.
4. Mendel, D.B., Laird, A.D., Smolich, B.D., Blake, R.A., Liang, C., Hannah, A.L., Shaheen, R.M., Ellis, L.M., Weitman, S., Shawver, L.K. and Cherrington, J.M. (2000) Anti-Cancer Drug Des. 15, 29-41.
5. Braud, E., Duflos, M., Nourrisson, M.R., Tonnerre, A., Picot, C., Le Baut, G., Renard, P., Pfeiffer, B. and Tucker, G. (2003) J. Enz. Inhib. Med. Chem. 18, 243-252.
6. Kadin, S.B. (1972) J. Med. Chem. 15, 551-552.
7. Sun, L., Tran, N., Tang, F., App, H., Hirth, P., McMahon, G. and Tang, C. (1998) J. Med. Chem. 41, 2588-2603.
8. Nicosia, R.F. and Ottinetti, A. (1990) Lab. Invest. 63, 115-122.
9. Montesano, R., Orci, L. and Vassalli, P. (1983) J. Cell Biol. 97, 1648-1652.
10. Knedler, A. and Ham, R.G. (1987) In Vitro Cell Dev. Biol. 23, 481-491.
11. Walter, R. and Zimmer, H. (1964) J. Heterocyclic Chem. 1, 205-206.
12. Walter, R., Zimmer, H. and Purcell, T.C. (1966) J. Org. Chem. 31, 3854-3857.
13. Takeuchi, Y., Choshi, T., Tomozane, H., Yoshida, H. and Yamato, M. (1990) Chem. Pharm. Bull. 38, 2265-2267.
14. Nicolaides, D.N., Adamopoulos, S.G., Lefkaditis, D.A., Litinas, K.E. and Tarantili, P.V. (1992) J. Chem. Soc., Perkin Trans. 1, 283-289.
15. Litinas, K.E. and Stampelos, X.N. (1992) J. Chem. Soc., Perkin Trans. 1, 2981-2984.
16. Gripenberg, J. and Juselius, B. (1954) Acta. Chem. Scand. 8, 734-737.
17. Molho, D. and Coillard, J. (1956) Bull. Soc. Chim. Fr., 78-93.
18. Levine, J., Eble, T.E. and Fischbach, H. (1948) J. Am. Chem. Soc. 60, 1930.
19. Czaplicki, S. and Kostanecki, St.V. (1909) Chem. Ber. 42, 827-838.
20. Kingsbury, C.A., Draney, D., Sopchik, A., Rissler, W. and Durham, D. (1976) J. Org. Chem. 41, 3863-3868.
21. Letcher, R.M. and Ng, K.W. (1989) J. Chem. Res. (S), 198-199.